Lifestyle DiseasesGastroenterology & Gut Health

Irritable Bowel Syndrome (IBS): Subtypes, Visceral Hypersensitivity, and Low-FODMAP Diet

Irritable Bowel Syndrome (IBS) is a disorder of gut-brain interaction (DGBI) affecting roughly 10% of the global population, characterized by recurrent abdominal pain associated with altered bowel habits. Review Rome IV diagnostic criteria, IBS subtypes (IBS-C, IBS-D, IBS-M), visceral hypersensitivity, Small Intestinal Bacterial Overgrowth (SIBO), and the 3-phase Low-FODMAP elimination and reintroduction protocol.

Published: 2026-09-12Reviewed: September 2026Updated: 2026-09-15 9 min read 2120 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Irritable Bowel Syndrome (IBS): Subtypes, Visceral Hypersensitivity, and Low-FODMAP Diet

Quick Summary & Key Findings

Irritable Bowel Syndrome (IBS) is diagnosed under Rome IV criteria as recurrent abdominal pain at least 1 day per week for 3 months, related to defecation and associated with a change in stool frequency or form. The most clinically validated dietary therapy is the 3-phase Low-FODMAP diet (Elimination, Reintroduction, and Personalization), which reduces poorly absorbed short-chain fermentable carbohydrates that cause gas distension, osmotic diarrhea, and visceral pain in sensitive guts.

For decades, patients presenting with chronic bloating, severe cramping, and unpredictable bowel habits were frequently told that their symptoms were 'all in their head' after routine colonoscopies and blood tests returned completely normal. Today, neurogastroenterology recognizes Irritable Bowel Syndrome (IBS) not as an imaginary complaint, but as a well-defined Disorder of Gut-Brain Interaction (DGBI).

In IBS, complex bidirectional dysregulation between the enteric nervous system (the 'second brain' in the gut) and the central nervous system produces visceral hypersensitivity—a lowered pain threshold where normal physiological intestinal gas and digestive contractions are perceived by the brain as sharp, distressing pain.

By classifying patients into precise clinical subtypes and applying the evidence-based 3-phase Low-FODMAP protocol developed by Monash University, clinicians and dietitians can resolve debilitating digestive symptoms in over 70% of IBS sufferers.

The Rome IV Diagnostic Criteria and IBS Subtypes

IBS is diagnosed clinically based on symptom patterns after excluding organic disease (celiac disease, IBD):
Rome IV Diagnostic Definition: Recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with 2 or more criteria: (1) Related to defecation (relieved or worsened by bowel movements), (2) Associated with a change in stool frequency, or (3) Associated with a change in stool appearance/form (Bristol Stool Scale).
IBS-C (Constipation-Predominant): >25% of bowel movements are hard/lumpy (Bristol 1–2), <25% are loose; managed with osmotic laxatives (polyethylene glycol) and secretagogues (lubiprostone, linaclotide).
IBS-D (Diarrhea-Predominant): >25% of bowel movements are mushy/watery (Bristol 6–7); managed with peripheral opioid agonists (loperamide, eluxadoline) or non-absorbable antibiotic rifaximin.
IBS-M (Mixed Bowel Habits): Alternating bouts of both constipation and diarrhea.
Red-Flag Alarm Symptoms (NOT IBS): Unintended weight loss, rectal bleeding, nocturnal diarrhea that wakes the patient from sleep, family history of colorectal cancer or IBD, onset after age 50, or elevated fecal calprotectin (requires diagnostic colonoscopy).

The 3-Phase Low-FODMAP Protocol (Monash University)

FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are short-chain carbohydrates that draw water into the small intestine through osmosis and are rapidly fermented by colonic bacteria into hydrogen and methane gas:
Phase 1: Strict Elimination (2 to 6 Weeks): Temporarily eliminate high-FODMAP foods: Fructose (high-fructose corn syrup, apples, honey), Lactose (cow's milk, soft cheeses), Fructans (wheat, onions, garlic), Galacto-oligosaccharides (beans, lentils), and Polyols (sorbitol, mannitol, stone fruits, sugar alcohols).
Phase 2: Systematic Reintroduction (6 to 8 Weeks): Reintroduce one specific FODMAP group at a time over 3 days (e.g., testing fructose with honey, fructans with garlic) while keeping the baseline diet low-FODMAP, identifying exact personal dietary triggers and tolerance thresholds.
Phase 3: FODMAP Personalization (Long-Term): Reintroduce all tolerated foods back into the diet, restricting only specific high-trigger foods. A strict Low-FODMAP diet must NEVER be followed permanently, as long-term restriction starves beneficial gut bifidobacteria.

Gut-Brain Neuromodulators and Psychological Therapies

Targeting the enteric nervous system provides symptom relief when dietary adjustments alone are insufficient:
Gut-Directed Hypnotherapy: Validated in randomized trials to produce symptom reductions matching the Low-FODMAP diet by retraining central sensory processing of gut signals.
Low-Dose Neuromodulators (Tricyclics like Amitriptyline 10–25 mg): Acts as central and visceral analgesics, reducing intestinal hypersensitivity and slowing transit in IBS-D.
Peppermint Oil (Enteric-Coated): Natural L-menthol blocks calcium channels in intestinal smooth muscle, providing rapid antispasmodic relief for postprandial cramping.

Frequently Asked Questions

R
Clinical Reviewer License Verified

Dr. Randhir Sud, MBBS, MD, DM, MAMS

Chairman, Institute of Digestive & Hepatobiliary Sciences, Medanta – The Medicity • MBBS, MD, DM (Gastroenterology)
Medical Review Board

Dr. Randhir Sud is the Chairman of the Institute of Digestive and Hepatobiliary Sciences at Medanta – The Medicity, Gurugram. Recipient of the Padma Shri award, he is a pioneer in therapeutic gastrointestinal endoscopy, pancreatic-biliary disorders, and digestive health with over 35 years of clinical practice.

License ID: DMC-09180
Chairman, Institute of Digestive and Hepatobiliary Sciences, Medanta – The Medicity, Gurugram, Delhi NCR
Medically evaluated on September 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. ACG Clinical Guideline: Management of Irritable Bowel Syndrome (2020-2026). [Access Resource Link] — The American Journal of Gastroenterology
  2. Clinical Research Faculty & Editorial Team. Efficacy of the Low FODMAP Diet for Treating Irritable Bowel Syndrome: The Evidence to Date (2020-2026). [Access Resource Link] — Clinical and Experimental Gastroenterology
  3. Clinical Research Faculty & Editorial Team. Rome IV Diagnostic Criteria for Disorders of Gut-Brain Interaction (2020-2026). [Access Resource Link] — Gastroenterology
Article Tools & Sharing:
Educational Resources
Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
CW
Carl W., PatientVerified Patient
•August 18, 2026

The detailed stage breakdown and laboratory biomarker tables helped me understand my recent lab results and collaborate much more effectively with my specialist.

Dr. S.K. Sarin, MBBS, MD, DM (Gastro), FNAHepatologist & Director, ILBS
August 19, 2026

Empowered patients who understand their biomarkers achieve the best long-term clinical outcomes, Carl. Keep working closely with your healthcare team.

NB
Nurse Brenda K., Clinical CoordinatorHealthcare Professional
•August 29, 2026

Clear explanation of etiology, dietary interventions, and pharmacological management. The safety callouts regarding when to seek immediate medical attention are especially valuable.

Dr. S.K. Sarin, MBBS, MD, DM (Gastro), FNAHepatologist & Director, ILBS
August 30, 2026

Highlighting clinical red flags ensures patient safety while providing robust home management literacy, Brenda. Thank you for your feedback!

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.